We report a case of a 60-year-old man with obstructive aortic prosthetic valve thrombosis (APVT). He was treated with low-dose (25 mg) slow infusion (6 hours) of intravenous tissue plasminogen activator (t-PA), and he suffered acute anterior myocardial infarction (MI) at the fourth hour of t-PA infusion. Infusion was kept on, and coronary reperfusion and successful lysis of APVT were achieved. Intravenous unfractionated heparin (UFH) was then started, however, on the third day following heparin treatment, heparin-induced thrombocytopenia (HIT) was recognized by a drop in the platelet count and rethrombosis of the prosthetic valve. Although no nonheparin anticoagulant was available, intravenous continuous infusion of streptokinase (SKZ) 250 000 U per day was administered for 5 days followed by transition to warfarin therapy. Successful lysis of the APVT was again achieved with this regimen and the patient was discharged after uneventful recovery. The patient remained well at 6 months and 1 year follow-up.
A 60-year-old man, with a history of bileaflet mechanical aortic prosthetic valve (APV) replacement 4 years ago, presented with dyspnea of 7 days (New York Heart Association Class II). He had suffered thromboembolic stroke 2 months before admission and he was treated with unfractionated heparin (UFH) for 10 days in a primary hospital. Although he was on oral anticoagulation with warfarin 5 mg per day, his international normalized ratio (INR) values were subtherapeutic for 6 months. Results of cardiopulmonary examination were unremarkable except for mildly muffled APV sounds with normal vital signs. Neurological examination revealed dysarthria and left hemiparesis. Cranial tomography revealed an old infarction area in the territory of right middle cerebral artery but no hemorrhage. Electrocardiogram (ECG) revealed normal sinus rhythm. Doppler transthoracic echocardiography (TTE) showed severely increased transprosthetic mean gradient of 60 mm Hg ( Figure 1A ). The left ventricular ejection fraction was 55%. Transesophageal echocardiogram (TEE) depicted a 1.1 Â 0.4 cm thrombus on APV ( Figure 1B ). Contrastenhanced 64-slice multidetector computerized tomography (MDCT) was also performed and a noncritical atherosclerotic lesion in the proximal segment of left anterior descending (LAD) coronary artery ( Figure 1C ) and a thrombus on the APV ( Figure 1D ) were evident.
Because the patient was deemed as a high-risk surgical candidate and reoperation was refused by the patient, we decided to institute thrombolytic therapy (TT). After explaining to the patient the risk of TT and obtaining informed consent, lowdose (25 mg), prolonged infusion (6 hours) of tissue plasminogen activator (t-PA) was started intravenously. In the fourth hour of the infusion, the patient complained of severe chest pain, and immediate ECG revealed acute anterior myocardial infarction (MI) with ST-segment elevation. A decision was made to keep on TT during the remaining 2 hours and to reevaluate the patient after completion of t-PA for the need of a successive TT session. In the fifth hour of TT, the patient suffered ventricular fibrillation and was then defibrillated successfully. The ECG after defibrillation revealed resolution of ST-segment elevations without any Q waves, and relief of angina occurred simultaneously, suggesting successful reperfusion. Transthoracic echocardiography after TT revealed decrease in mean transprosthetic gradient to 24 mm Hg and ejection fraction to 45% with hypokinesia of anteroseptal segment of left ventricle.
Unfractionated heparin infusion of 1000 U per hour with a target activated partial thromboplastin time between 1.5 and 2.5 times the control was started just after TT completion. Repeat MDCT was performed for further APV and coronary evaluation after 3 days of UFH treatment. Multidetector computerized tomography revealed a persisting thrombus on APV, even larger than the former one ( Figure 2A and B) , and ulceration and thrombosis of preexisting noncritical lesion in proximal LAD causing 95% stenosis ( Figure 2C and D). Repeat TTE revealed recurrence of elevated transprosthetic mean gradient to 60 mm Hg. Laboratory data revealed gradual drop of platelets from a baseline value of 135 000 on admission to 91 000 after 24 hours and to 47 000 after 72 hours of UFH initiation. Hence, heparin-induced thrombocytopenia (HIT) was strongly suspected and heparin treatment was immediately discontinued. Blood was drawn for detecting anti-Platelet Factor 4 (PF4)/heparin antibodies using the rapid Particle Immuno-Filtration Assay (HealthTest Heparin/PF 4 Antibody Assay, Health-Chem Diagnostics LLC Pompano Beach, FL USA), and the result was positive. Although no direct thrombin inhibitor or antifactor Xa agent was available, we decided to administer streptokinase (SKZ) continuously, with an infusion rate of 250 000 U per day. Oral warfarin 10 mg per day was also initiated as the platelet levels reached to 98 000 at 48th hour of SKZ infusion. After achieving an INR of 2.1 on the fifth day of warfarin therapy, SKZ was ceased without any complication. Repeat TEE revealed disappearance of thrombus on APV and decrease in transprosthetic gradient to 22 mm Hg. Percutaneous coronary intervention (PCI) of subtotal LAD lesion was not considered because a nonheparin anticoagulant medication was unavailable to perform the procedure safely and because he was already under treatment with warfarin with effective INR level and was asymptomatic.
The patient had an uneventful recovery and was discharged on warfarin anticoagulation with a target INR of 3.5 to 4 as well as antiplatelet therapy with aspirin. He remained well at 6 months and 1 year follow-up.
Discussion
Prosthetic heart valve thrombosis (PHVT) is a rare but serious complication. 1 The incidence of PHVT in aortic position was 0.1/100 patient years. 2 Transesophageal echocardiogram is the method of choice for the evaluation of PHVT. However, aortic position is a limitation for the evaluation of PHVT by TEE. 3, 4 In this context, we have recently presented that MDCT may be a useful technique in the management of PHVT. 5 In our patient, MDCT depicted APV thrombus with larger dimensions as compared to TEE, possibly caused by poor sonographic image quality of prosthesis located at the aortic position.
Although surgery is recommended traditionally, 6 recent evidence suggests that TT must be considered the first-line treatment in patients with PHVT, unless contraindicated. 3, 7, 8 While previous reports indicate higher incidence of embolic and hemorrhagic complications with rapid thrombolytic infusions, we have previously 8 and recently 9 shown that intravenous slow infusion of SKZ and low-dose (25 mg) slow infusion (6 hours) of t-PA given in discrete successive sessions guided by serial TEE can be achieved with a low risk of complication and high rate of success. Based on our previous experience, a decision was made to administer low-dose prolonged infusion of t-PA to our patient. Although the transprosthetic gradients decreased significantly with this treatment regimen, MI, developed at the fourth hour of t-PA infusion.
In this particular patient, 4 alternative ways may be considered for managing MI: (1) to undertake a primary PCI, (2) to continue t-PA infusion with the same regimen during the remaining 2 hours with successive episodes if needed, (3) to consider switching the therapy to classical MI TT regimen by increasing the dose to 100 mg in 90 minutes, 10 and (4) to perform surgery. Thrombolytic therapy was judged to be more advantageous and beneficial and preferred to PCI due to the potential risk of catheter-induced embolism of APV thrombus during the PCI procedure. Surgery was also not performed due to very high operative risk and patient preference. Nevertheless, classical MI TT regimen was avoided because of the increased risk of intracranial hemorrhage associated with recent stroke and the risk of reembolization due to rapid infusion. Hence, low-dose prolonged infusion of t-PA was favored and kept on during the remaining 2 hours of protocol. Consequently, reperfusion was achieved 1 hour after the MI.
Heparin-induced thrombocytopenia is caused by antibodies to the complex of PF4/heparin, which develop 5 to 10 days after exposure to heparin. 11 In addition to a drop in the platelet count, patients who develop HIT have 30% to 75% risk of thrombotic complications, and cessation of heparin without effective alternative anticoagulation is not sufficient to reduce this risk. 12 Direct thrombin inhibitors and antifactor Xa agents are the drugs of choice in the management of HIT. 12 When long-term oral anticoagulation is indicated in a patient with HIT, transition to warfarin therapy should be delayed until platelet count recovers. 12 Symptoms of HIT can develop rapidly in patients reexposed to heparin (within past 100 days), in whom HIT antibodies are still present. 11 Relevant to the present case, the patient was exposed to UFH for 10 days in the recent past (within 2 months) and was subsequently ineffectively anticoagulated on warfarin. It is possible that the patient developed HIT antibodies at the time of the heparin treatment for stroke (with or without recognized thrombocytopenia), which eventually led to thrombotic complication that caused the presenting dyspnea 2 months later. That HIT was ongoing is suggested by the low baseline platelet count along with evidence of thrombosis at the time of the current hospitalization. The presence of HIT antibodies would explain the worsening thrombotic complications that quickly developed following the reexposure to heparin after TT. The rapid development of new thromboses together with the drop in platelet count within 1 to 3 days of administration of heparin suggest that the patient may have had circulating HIT antibodies when he was admitted and that HIT may have been the underlying cause of the initial PHVT. Laboratory tests confirmed the clinical diagnosis of HIT. In the absence of direct thrombin inhibitors or antifactor Xa agents, the thrombotic complications of HIT were successfully treated with SKZ infusion. The APV and coronary artery thrombi were lysed without complication, and platelet count recovered, allowing transition to warfarin therapy.
In conclusion, acute MI during thrombolysis of PHVT associated with HIT is an extremely rare clinical scenario. The case demonstrates successful management of HIT thrombosis using slow infusion of SKZ followed by transition to warfarin.
